According to a company source, unlike other ACE inhibitors, Fosinopril has a compensatort dual route of elimination and is cleared both through the liver and the kidney. Thus, in patients with diminished renal function increased hepatic clearance of Fosinopril is noted and in patients with diminished hepatic function increased renalclearance occurs. Due to this compensatory elimination, fosinopril therapy does not require dosage adjustments unlike other ACE inhibitors.
Fosinopril is also a very useful alternative for treating patients with essential hypertension and is equally effective in elderly, especially with renal compromise that is common in these patients.
The cardiovascular market is valued at around Rs 1,200 crore in India with ACE inhibitors contributing Rs 163 crore and growing at the rate of 20 per cent. CPL already has a major share of this market with its Envas brand enjoying a 23 per cent share. The introduction of Fovas is not only expected to strengthen the cardio basket of the company but also revolutionalise cardiovascular therapy.